Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

被引：0
|
作者：
Fosser, C. [1 ]
Roberts, J. [2 ]
Tortorici, M. [2 ]
Jacobs, I. [2 ]
Sidhu, J. [2 ]
机构：
[1] Cytel, Cambridge, MA USA
[2] CSL Behring, King Of Prussia, PA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-010
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [31] Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice
    Le Quellec, Sandra
    Dane, Allison P.
    Negrier, Claude
    Dargaud, Yesim
    Nathwani, Amit C.
    Enjolras, Nathalie
    BLOOD, 2017, 130
  • [32] STABLE FIX EXPRESSION AND DURABLE REDUCTIONS IN BLEEDING AND FACTOR IX CONSUMPTION FOR UP TO 4 YEARS FOLLOWING AMT-060 GENE THERAPY IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B
    Leebeek, F. W.
    Meijer, K.
    Coppens, M.
    Kampmann, P.
    Klamroth, R.
    Schutgens, R.
    Castaman, G.
    Seifried, E.
    Schwable, J.
    Bonig, H.
    Sawyer, E. K.
    Miesbach, W.
    HAEMOPHILIA, 2020, 26 : 78 - 78
  • [33] Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B
    Miesbach, Wolfgang
    Meijer, Karina
    Coppens, Michiel
    Kampmann, Peter
    Dr Klamroth
    Schutgens, Roger
    Castaman, Giancarlo
    Seifried, Erhard
    Schwaeble, Joachim
    Bonig, Halvard
    Sawyer, Eileen K.
    Leebeek, Frank W. G.
    BLOOD, 2019, 134
  • [34] AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years
    Leebeek, Frank W. G.
    Meijer, Karina
    Coppens, Michiel
    Kampmann, Peter
    Klamroth, Robert
    Schutgens, Roger
    Castaman, Giancarlo
    Seifried, Erhard
    Schwaeble, Joachim
    Bonig, Halvard
    Sawyer, Eileen K.
    Miesbach, Wolfgang A.
    BLOOD, 2020, 136
  • [35] . Therapeutic Factor IX (FIX) Activity after Single Treatment with AMT-060 (AAV5-FIX) in Hemophilia B Patients with Pre-Existing Anti-AAV5 Humoral Immunity
    Majowicz, Anna
    Nijmeijer, Bart
    Lampen, Margit H.
    Spronck, Lisa
    de Haan, Martin
    Petry, Harald
    van Deventer, Sander
    Meyer, Christian
    Tangelder, Marco
    Ferreira, Valerie
    MOLECULAR THERAPY, 2018, 26 (05) : 458 - 458
  • [36] Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B
    Pipe, Steven
    van der Valk, Paul
    Verhamme, Peter
    Kampmann, Peter
    Leebeek, Frank W. G.
    Coppens, Michiel
    Meijer, Karina
    Raheja, Priyanka
    Key, Nigel S.
    Visweshwar, Nathan
    Young, Guy
    Lemons, Richard S.
    Klamroth, Robert
    Miesbach, Wolfgang
    Astermark, Jan
    O'Connell, Niamh
    Kazmi, Rashid Saeed
    Galante, Nicholas
    LeQuellec, Sandra
    Monahan, Paul
    Hermans, Cedric R.
    BLOOD, 2023, 142
  • [37] Development of an Agent-Based Model to Investigate Response Durability in Hemophilia B Patients Treated with the AAV-Based Coagulation Factor IX (FIX) Gene Therapy Etranacogene Dezaparvovec
    Li, Yuezhe
    Nandy, Partha
    Jordie, Eric
    Peppel, Karsten
    Knab, Timothy
    Kirouac, Daniel
    Wilkins, A. Katharina
    Nuthalapati, Silpa
    BLOOD, 2024, 144 : 7455 - 7456
  • [38] SAFETY AND EFFICACY OF MONOCLONAL-ANTIBODY (MAB)-PURIFIED FACTOR-IX FOR PROPHYLAXIS AGAINST BLEEDING IN HEMOPHILIA-B PATIENTS UNDERGOING SURGICAL-PROCEDURES
    SHAPIRO, A
    WHITE, GC
    PITEL, P
    BERGMAN, GE
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1022 - 1022
  • [39] Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B
    Windyga, Jerzy
    Lissitchkov, Toshko
    Stasyshyn, Oleksandra
    Mamonov, Vasily
    Rusen, Luminita
    Luis Lamas, Jose
    Oh, Myungshin
    Chapman, Miranda
    Fritsch, Sandor
    Pavlova, Borislava G.
    Wong, Wing Yen
    Abbuehl, Brigitt E.
    BLOOD, 2012, 120 (21)
  • [40] Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B
    Atsuko Nishiyama
    Kenichi Ogiwara
    Kuniyoshi Mizumachi
    Naoki Hashimoto
    Masahiro Takeyama
    Keiji Nogami
    International Journal of Hematology, 2022, 116 : 778 - 786
12345